Abstract
FDA committee recommends Amgen's denosumab, for the treatment, but not prevention, of bone loss, while Lilly decides not to submit arzoxifene for regulatory review after 5-year trial.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Opar, A. Late-stage osteoporosis drugs illustrate challenges in the field. Nat Rev Drug Discov 8, 757–758 (2009). https://doi.org/10.1038/nrd3015
Issue Date:
DOI: https://doi.org/10.1038/nrd3015
This article is cited by
-
Dual roles of QOA-8a in antiosteoporosis: a combination of bone anabolic and anti-resorptive effects
Acta Pharmacologica Sinica (2018)
-
News in brief
Nature Reviews Drug Discovery (2010)
